Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Clin Cancer Res. 2019 May 6:10.1158/1078-0432.CCR-19-0173. doi: 10.1158/1078-0432.CCR-19-0173

Figure 2. Gene-expression based biomarker correlation with chemotherapy response at surgery and long-term breast cancer outcomes.

Figure 2.

Macrophage signature in the DFCI cohort was calculated using NanoString PanCancer Immune (PCI) Panel, and correlation with RCB status was assessed (A). M1-like macrophage inferred proportion by CIBERSORT and MDSC signature score(43) was calculated from microarray data from our prior meta-analysis of HR+/HER2− tumors treated with neoadjuvant chemotherapy(17), and correlation with RCB status was assessed (B-C). For A-C, due to a paucity of complete responses, pCR (RCB 0) and RCB-I were grouped together. Each boxplot represents the 25th to 75th percentile with the median indicated as the central line and whiskers indicating 1.5 × interquartile range. Association of M1-like macrophage or CD8 cell proportion by CIBERSORT with distant metastasis-free survival was assessed (D-E).